Last reviewed · How we verify

Fluticasone Furoate Inhalation Powder

GlaxoSmithKline · Phase 3 active Small molecule

Fluticasone Furoate Inhalation Powder is a Inhaled corticosteroid Small molecule drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Asthma maintenance treatment, Chronic obstructive pulmonary disease (COPD).

Fluticasone furoate is a corticosteroid that binds to glucocorticoid receptors in the lungs to reduce inflammation and suppress immune responses in the airways.

Fluticasone furoate is a corticosteroid that binds to glucocorticoid receptors in the lungs to reduce inflammation and suppress immune responses in the airways. Used for Asthma maintenance treatment, Chronic obstructive pulmonary disease (COPD).

At a glance

Generic nameFluticasone Furoate Inhalation Powder
SponsorGlaxoSmithKline
Drug classInhaled corticosteroid
TargetGlucocorticoid receptor
ModalitySmall molecule
Therapeutic areaRespiratory / Pulmonology
PhasePhase 3

Mechanism of action

As an inhaled corticosteroid, fluticasone furoate acts locally in the respiratory tract by activating glucocorticoid receptors on immune cells and epithelial cells. This leads to decreased production of inflammatory mediators, reduced recruitment of inflammatory cells, and suppression of airway hyperresponsiveness. The furoate ester formulation provides enhanced potency and prolonged local activity compared to other fluticasone formulations.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Fluticasone Furoate Inhalation Powder

What is Fluticasone Furoate Inhalation Powder?

Fluticasone Furoate Inhalation Powder is a Inhaled corticosteroid drug developed by GlaxoSmithKline, indicated for Asthma maintenance treatment, Chronic obstructive pulmonary disease (COPD).

How does Fluticasone Furoate Inhalation Powder work?

Fluticasone furoate is a corticosteroid that binds to glucocorticoid receptors in the lungs to reduce inflammation and suppress immune responses in the airways.

What is Fluticasone Furoate Inhalation Powder used for?

Fluticasone Furoate Inhalation Powder is indicated for Asthma maintenance treatment, Chronic obstructive pulmonary disease (COPD).

Who makes Fluticasone Furoate Inhalation Powder?

Fluticasone Furoate Inhalation Powder is developed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).

What drug class is Fluticasone Furoate Inhalation Powder in?

Fluticasone Furoate Inhalation Powder belongs to the Inhaled corticosteroid class. See all Inhaled corticosteroid drugs at /class/inhaled-corticosteroid.

What development phase is Fluticasone Furoate Inhalation Powder in?

Fluticasone Furoate Inhalation Powder is in Phase 3.

What are the side effects of Fluticasone Furoate Inhalation Powder?

Common side effects of Fluticasone Furoate Inhalation Powder include Tremor, Headache, Palpitations, Muscle cramps, Throat irritation.

What does Fluticasone Furoate Inhalation Powder target?

Fluticasone Furoate Inhalation Powder targets Glucocorticoid receptor and is a Inhaled corticosteroid.

Related